Product Candidate
Discovery
PRECLIN
PHASE 1
PHASE 2
PHASE 3
MARKET
Status
HCV Inhibitor
glecaprevir-containing pan-genotypic 2-DAA combo
Pan-genotypic: Marketed by AbbVie
RSV Inhibitor
EDP-938
Phase 2b "RSVP" study ongoing
NASHFXR Agonist
EDP-305
Phase 2a "ARGON-1" study complete
HBVCore Inhibitor
EDP-514
Phase 1a study complete
NASHFXR Agonist Follow-on
EDP-297
Preclinical
hMPV Inhibitor
Discovery
COVID-19 SARS-CoV-2 Inhibitor
Discovery
RSV, HBV, NASH, other
Discovery or Preclinical

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed as MAVYRET (U.S.) and MAVIRET (ex-U.S.), it replaces VIEKIRA PAK (no longer sold in the U.S.) and VIEKIRAX (sold primarily in select jurisdictions where MAVIRET is not yet approved).